Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Interleukin (IL) 33 is a potent proinflammatory cytokine and a potential target in age-related macular degeneration (AMD) pathophysiology. This study evaluated RO7303359, an anti-IL-33 fragment antigen-binding region (Fab) targeting the IL-33/serum stimulation-2 (ST2) pathway, in patients with geographic atrophy (GA) secondary to AMD.
Design: Phase I, open-label, multicenter, single-dose, dose-escalation study.
Participants: Patients with GA secondary to AMD.
Methods: Patients received a single intravitreal (IVT) injection of RO7303359 (dose range, 1-20 mg).
Main Outcome Measures: The primary objective was to evaluate the safety and tolerability of RO7303359. The secondary objectives included assessing pharmacokinetics (PK), immune response, and pharmacodynamic (PD) biomarker activity. Pharmacodynamic biomarkers assessed in aqueous humor included CC motif chemokine ligand 2, CXC motif chemokine ligand 10, IL-6, and intercellular adhesion molecule 1.
Results: Thirty-seven patients enrolled in the dose cohorts. Single IVT doses of RO7303359 demonstrated an acceptable safety profile up to 20 mg, with mild ocular adverse events reported. Pharmacokinetics analysis revealed dose-proportional exposure within expected ranges for an IVT-administered Fab. No treatment-emergent antidrug antibodies were observed. Evaluation of changes in aqueous humor PD biomarker levels failed to demonstrate a discernible effect on IL-33/ST2 pathway activity.
Conclusions: In this trial (ClinicalTrials.gov identifier, NCT04615325), while RO7303359 exhibited acceptable safety and PK profiles, absence of demonstrable effects on the IL-33/ST2 pathway using aqueous PD biomarkers resulted in discontinuation of development in GA. Further work is needed to evaluate the relevance of the IL-33/ST2 pathway in the pathophysiology of AMD.
Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177163 | PMC |
| http://dx.doi.org/10.1016/j.xops.2025.100800 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Electroacupuncture Protects Against Post-stroke Cognitive Impairment by Promoting an IL-33/ST2 Axis-Mediated Microglia M2 Polarization.
Neurochem Res
August 2025
Rehabilitation Center, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Post-stroke cognitive impairment (PSCI) is a common and debilitating complication of stroke that significantly hinders rehabilitation. Electroacupuncture (EA), which integrates traditional acupuncture with electrical stimulation, has been widely applied in clinical practice and shown remarkable efficacy in treating PSCI. However, its underlying mechanisms remain largely unexplored.
View Article and Find Full Text PDFLuteolin attenuates type 2 inflammation in asthmatic mice induced by OVA by regulating IL-33/ST2- GSK3β-M2 macrophage polarization.
Mol Immunol
October 2025
Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China. Electronic address:
Allergic asthma is a prevalent non-infectious inflammatory disease characterized by type 2 inflammation. Although multiple treatment options are available, their efficacy is often limited due to the heterogeneous nature of asthma. Luteolin (LUT), a naturally occurring flavonoid, has demonstrated therapeutic potential in various inflammatory conditions.
View Article and Find Full Text PDFThe IL-33/ST2/ILC2 pathway in kidney disease: balancing inflammation, fibrosis, and repair.
Am J Physiol Cell Physiol
September 2025
Department of Microbiology and Immunology, Showa Medical University Graduate School of Medicine, Tokyo, Japan.
Group 2 innate lymphoid cells (ILC2s) are tissue-resident immune cells that respond rapidly to epithelial-derived cytokines such as interleukin (IL)-33, producing type 2 cytokines including IL-5 and IL-13. Although ILC2s are well recognized for their roles in regulating inflammation and tissue remodeling in barrier organs, their functions in the kidney have only recently gained attention. In this review, we summarize the localization, activation, and effector functions of ILC2s in the kidney and explore their immunoregulatory interactions with macrophages, particularly in promoting M2 polarization.
View Article and Find Full Text PDFThe Role of Type 2 Innate Lymphoid Cells in Adenoid Hypertrophy with Allergic Rhinitis Among Children and Related Potential Therapeutic Targets.
J Inflamm Res
July 2025
Department of Pediatric Otolaryngology, Shenzhen Hospital, Southern Medical University, Shenzhen, People's Republic of China.
Objective: Innate lymphoid cells (ILC) are a heterogeneous group of immune cells implicated in immune diseases. However, their specific roles in adenoid hypertrophy (AH), AH with allergic rhinitis (AH+AR), and AH with otitis media with effusion (AH+OME) remain poorly understood. This study aimed to characterize ILC subsets and their association with immunological profiles in these conditions.
View Article and Find Full Text PDFPhase I Study of the Anti-interleukin 33 Fragment Antigen-Binding Region RO7303359 in Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Ophthalmol Sci
April 2025
Early Clinical Development, Genentech, Inc, South San Francisco, California.
Purpose: Interleukin (IL) 33 is a potent proinflammatory cytokine and a potential target in age-related macular degeneration (AMD) pathophysiology. This study evaluated RO7303359, an anti-IL-33 fragment antigen-binding region (Fab) targeting the IL-33/serum stimulation-2 (ST2) pathway, in patients with geographic atrophy (GA) secondary to AMD.
Design: Phase I, open-label, multicenter, single-dose, dose-escalation study.